Tehran University of Medical Sciences Journal of Pharmacoeconomics and Pharmaceutical Management 2383-4498 10 4 2024 10 14 23 31 EN JEROME KOUAME UNIVERSITY FELIX HOUPHOUET BOIGNY Régine Attia-Konan https://orcid.org/0000-0002-2146-9110 Kouame Koffi https://orcid.org/0000-0002-2146-9110 Paul Yapo Yapi https://orcid.org/0000-0002-2146-9110 Serge Oga https://orcid.org/0000-0002-2146-9110 2024 12 17 Background: Expenditure related to medicines has increased significantly in several countries. This study aimed to describe medicine expenditure trends at the Mutual Insurance Company for Civil Servers and Agents of the State of Côte d’Ivoire (MUGEFCI) between 2014 and 2018.   Methods: We conducted a retrospective analysis of the MUGEFCI's medicine expenditures. Beneficiaries who used at least one drug reimbursed between 1 January 2014 and 31 December 2018 were included in the study. Expenditure was estimated using public pharmacy prices. Beneficiaries were described by ATC class and age group. Results: In 2014, the medicine expenditure was XOF 14.720 billion (approximately € 22.44 million), which increased by 63.21% in 2018. The medicine classes that incurred the highest expenditures were, for the first level (ATC main group), anti-infectives for systemic use (23.84%), and cardiovascular medicines (15.23%). Anti-parasitic products, insecticides, and repellents (9.79%) and medicines for the alimentary tract and metabolism (9.67%) were also used. Total expenditure was most important for young adults aged 35-45 years. Conclusion: Medicine expenditures have increased significantly. The rational use of medicines and control of the expenditure they generate is a major challenge to guarantee access to medicines.   https://jppm.tums.ac.ir/index.php/jppm/article/view/243